Talawar Therapeutics merges with JATT II Acquisition to list on Nasdaq as AstraZeneca reports Phase 3 success in pediatric bone disease
read at Endpoints ↗DealPositive
Talawar Therapeutics announced a combination with blank‑check company JATT II Acquisition Corp, a deal that will place Talawar on the Nasdaq exchange.
The SPAC transaction gives Talawar public‑market access and capital to advance its development pipeline.
Separately, AstraZeneca reported positive Phase 3 trial results for its therapy aimed at a rare bone disease affecting children.
The news underscores ongoing biotech financing activity and encouraging clinical outcomes in the sector.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone disease”
read at Endpoints ↗79 words · retrieved Jul 1
comments(0)
5-min edit window · permanent after that